Skip to content
Download PDF

Hemoptysis

Part 2: Cardinal Manifestations and Presentation of Diseases · Part 2 – Cardinal Manifestations & Presentation · Chapter 41

Key Clinical Points

  1. Hemoptysis is defined as the expectoration of blood originating from the lower respiratory tract.
  2. Massive hemoptysis is defined as expectorating >150 mL in 24 hours or a bleeding rate of ≥100 mL/h.
  3. Life-threatening hemoptysis is characterized by abnormal gas exchange, hemodynamic compromise, or threat for airway obstruction.
  4. Most hemoptysis originates from the high-pressure bronchial circulation (from the aorta), making it difficult to control.
  5. Common causes vary by region: viral bronchitis and bronchiectasis in the US; tuberculosis globally.
  6. Rasmussen's aneurysm is a specific cause of massive hemoptysis in tuberculosis.
  7. Pulmonary emboli rarely present with frank blood or hemoptysis.
  8. Diffuse alveolar hemorrhage (DAH) typically presents with ground-glass opacities and is not often associated with hemoptysis.
  9. Bronchogenic carcinomas (especially small-cell and squamous cell) are common causes of massive hemoptysis due to their central location.
  10. Mortality in severe cases is primarily due to asphyxiation from airway obstruction rather than exsanguination.

DEFINITION & OVERVIEW

• Definition: Hemoptysis is the expectoration of blood originating from the lower respiratory tract. • Differential Diagnosis (Source): Must be distinguished from hematemesis (GI tract) or epistaxis (nasal cavity). • Clinical Importance: The volume and frequency of expectorated blood are critical for determining management. • Common Findings: Patients with chronic cough and normal findings on chest examination, lung function testing, oxygenation assessment, and chest CT can be reassured regarding the absence of serious pulmonary pathology.

Table 41-1: Definition of Massive vs. Life-Threatening Hemoptysis • Non-Massive: ◦ Volume: <150 mL in 24h ◦ Bleeding Rate: <100 mL/h ◦ Clinical Status: Stable ◦ Mortality Risk: Low • Massive / Life-Threatening: ◦ Volume: >150 mL in 24h ◦ Bleeding Rate: ≥100 mL/h ◦ Clinical Status: Abnormal gas exchange, hemodynamic compromise, or threat for airway obstruction ◦ Mortality Risk: High (Asphyxiation > Exsanguination) • Prevalence: Life-threatening hemoptysis accounts for only 5–15% of cases.

EPIDEMIOLOGY

• Regional Variations: ◦ United States: Most common causes are viral bronchitis, bronchiectasis, or malignancy. ◦ Global: Tuberculosis is a primary cause of hemoptysis. • Environmental Factors: ◦ Air pollution (cooking smoke, industrial chemicals) leads to chronic cough and lower respiratory tract disease. ◦ Management: Focuses on improving environmental air quality (e.g., stove chimneys), removal from exposure, and use of face masks.

Global Considerations

• Tuberculosis: In endemic areas, chronic cough requires evaluation via chest imaging and sputum analysis. • Paragonimiasis: Can mimic tuberculosis; common in Southeast Asia and China (associated with raw crayfish ingestion).

ETIOLOGY & PATHOPHYSIOLOGY

• Anatomical Basis: ◦ Pulmonary Circulation: Low-pressure system essential for gas exchange. ◦ Bronchial Circulation: High-pressure system originating from the aorta; supplies airways and can neovascularize tumors, dilated airways in bronchiectasis, and cavitary lesions. ◦ Clinical Significance: Most hemoptysis originates from the bronchial circulation, making it difficult to control. • Infectious Etiologies: ◦ Viral bronchitis: Most common cause of small-volume hemoptysis. ◦ Bacterial superinfection: Common in chronic bronchitis (S. pneumoniae, H. influenzae, M. catarrhalis). ◦ Bronchiectasis: Dilated, inflamed, and highly vascular airways; significant source of massive hemoptysis. ◦ Tuberculosis: Cavitary disease is a common source; Rasmussen's aneurysm (erosion of a pulmonary artery aneurysm into a preexisting cavity) is a rare but serious cause. ◦ Other Infections: Fungal infections (Aspergillus mycetomas), Nocardia, non-tuberculous mycobacteria, and pulmonary abscesses/necrotizing pneumonia (S. aureus, K. pneumoniae). ◦ Paragonimiasis: Mimics tuberculosis; common in Southeast Asia and China. • Malignancy: ◦ Bronchogenic carcinoma: Common cause of both massive and nonmassive hemoptysis. ◦ High Risk: Small-cell and squamous cell carcinomas (central location) are more likely to erode into major pulmonary vessels. ◦ Other: Carcinoid tumors, metastases (melanoma, sarcoma, breast, colon), Kaposi's sarcoma (highly vascular in AIDS). • Vascular & Mechanical Causes: ◦ Pulmonary Embolism: Rarely causes hemoptysis; frank blood is not a typical presentation. ◦ Arteriovenous Malformation: Can be a source of bleeding. ◦ Aortobronchial Fistula: Rare; results from aortic pathology (aneurysm/pseudoaneurysm) → massive hemoptysis. ◦ Diffuse Alveolar Hemorrhage (DAH): Not typically associated with hemoptysis; presents as ground-glass opacities. ◦ Pulmonary Endometriosis: Causes cyclical bleeding (catamenial hemoptysis). ◦ Other: Foreign body aspiration, procedural complications (pulmonary vein isolation, pulmonary artery catheters), and vaping-induced lung injury. ◦ Coagulopathy: Thrombocytopenia can cause hemoptysis from minor insults.

CLINICAL FEATURES

• History Taking: ◦ Pattern, severity, and quantity of hemoptysis. ◦ Sputum description: flecks of blood, pink-tinged, frank blood, or clot. ◦ Quantification: Use references like cups (1 U.S. cup = 236 mL). ◦ Risk factors: Smoking history, unintentional weight loss (malignancy). ◦ Infection signs: Preceding fevers, cough, sputum production. ◦ Chronic conditions: Cystic fibrosis or chronic bronchiectatic diseases. ◦ Pseudohemoptysis screening: Upper airway or gastrointestinal sources. • Physical Examination: ◦ Life-threatening signs: Hypoxemia, tachycardia, hemodynamic instability. ◦ Extrapulmonary sites: Nasal and oral cavities. ◦ Lung auscultation: Suggests laterality. ◦ Other findings: Clubbing (chronic disease/malignancy), bleeding diathesis (ecchymoses, petechiae), telangiectasias, or skin rash (vasculitis).

DIFFERENTIAL DIAGNOSIS

• Infection: Viral bronchitis, bacterial superinfection (S. pneumoniae, H. influenzae, M. catarrhalis), tuberculosis (cavitary, Rasmussen's aneurysm), fungal infections (Aspergillus mycetoma, Nocardia), non-tuberculous mycobacteria, paragonimiasis, pulmonary abscesses. • Malignancy: Bronchogenic carcinoma (central/squamous/small-cell), carcinoid tumors, metastases (melanoma, sarcoma, breast, colon), Kaposi's sarcoma. • Vascular: Pulmonary embolism, arteriovenous malformation, diffuse alveolar hemorrhage, aortobronchial fistula. • Mechanical/Other: Pulmonary endometriosis, foreign body aspiration, procedural complications (pulmonary vein isolation, pulmonary artery catheters), vaping-induced lung injury.

DIAGNOSTIC APPROACH

  1. Initial Assessment: ◦ Assess for life-threatening signs: Hypoxemia, tachycardia, hemodynamic instability. ◦ Examine nasal and oral cavities to rule out extra-pulmonary bleeding. ◦ Quantify volume (e.g., using cups) and describe sputum appearance. ◦ Screen for pseudohemoptysis (upper airway or GI sources).
  2. Imaging & Laboratory: ◦ Chest X-ray (CXR) and CT scan: Note that tumors, early ILD, bronchiectasis, and atypical mycobacteria may be missed on CXR. ◦ Laboratory studies: CBC, UA, serum creatinine, infection studies, and coagulation studies.
  3. Evaluation of Bleeding Status: ◦ Determine if bleeding is active or has stopped to guide intervention. ◦ If bleeding stops → Treat underlying cause. ◦ If bleeding continues → Proceed to interventional procedures (Embolization or resection).

MANAGEMENT & TREATMENT

  1. Immediate Stabilization: ◦ For life-threatening hemoptysis (hypoxemia, tachycardia, hemodynamic instability) → Protect airway.
  2. Diagnostic Workup: ◦ Perform CBC, CXR, CT scan, and UA.
  3. Interventional Decisions (Based on Figure 41-1): ◦ Step 1: Quantify amount of bleeding. ◦ Path A (Massive): → Protect airway. ◦ Path B (Nonmassive): → Identify Risk factors. ◦ Branch B1 (No risk factors): → Treat underlying cause. ◦ Branch B2 (Risk factors present): ◦ If bleeding stops → Proceed to CT scan → Bronchoscopy → Treat underlying cause. ◦ If bleeding continues → Embolization or resection.

PROGNOSIS & COMPLICATIONS

• Mortality Risk: ◦ High in life-threatening cases (5–15% of all hemoptysis). ◦ Primary cause of death: Asphyxiation from blood filling the airways and airspaces. ◦ Secondary risk: Exsanguination (rare).

SPECIAL CONSIDERATIONS

• Global & Environmental: ◦ Tuberculosis and Paragonimiasis in endemic areas. ◦ Impact of air pollution on chronic cough and lung disease. • Coagulopathy & Procedures: ◦ Thrombocytopenia: Even minor insults can cause hemoptysis. ◦ Procedural risks: Pulmonary vein isolation (pulmonary vein stenosis) or pulmonary artery catheters (rupture if distal balloon is inflated).

KEY PEARLS & CLINICAL TRAPS

• Source of Bleeding: Most hemoptysis comes from the high-pressure bronchial circulation → difficult to control. • Massive Definition: >150 mL in 24h or ≥100 mL/h. • Life-Threatening Criteria: Asphyxiation risk (airway obstruction) is more common than exsanguination. • Imaging Note: Patients with chronic cough and normal findings on CXR, lung function, oxygenation, and CT can be reassured of serious pulmonary pathology. • Pulmonary Embolism: Rarely presents with frank blood/hemoptysis. • DAH: Typically shows ground-glass opacities; not usually associated with hemoptysis.